- United States
- Our innovation
Our innovation
We innovate with purpose to lead where medicine is going.
Our focus areas
Our discovery, product development and supply process
With our cross-functional approach to innovation, deep expertise, and global footprint, we aim to develop therapies for patients by inventing, licensing and acquiring new molecular entities and exploring new pathways and multi-modality treatment approaches.
23-255-richard-tillyer-part-1-who-we-are-1.mp4
23-255-richard-tillyer-part-1-who-we-are-1.mp4
Research & development
We believe there are no limits to what science can do. We work to bring breakthroughs beyond medicine to help transform patients’ lives.
Our pipeline
Our robust pipeline spans multiple focus areas with a number of programs in development, as well as select novel therapy programs recently approved, or with potential filings in the United States/European Union.
Data science and digital health
Data science and digital health accelerate our R&D engine across the entire value-chain – from target discovery and patient segmentation to drug design, CMC process optimization and all facets of clinical development.
Latest news
TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
Biweekly dosing with TECVAYLI®, the first approved BCMA-targeting bispecific antibody, provides patients with dosing flexibility
Johnson & Johnson’s nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN)
Breakthrough Therapy Designation for nipocalimab based on results from the Phase 2 UNITY clinical trial for HDFN Phase 3 clinical trial enrollment underway, representing the only therapy reported to be under clinical development for this serious, life-threatening and rare condition
Johnson & Johnson highlights innovation in hemolytic disease of the fetus and newborn (HDFN) at the Society for Maternal-Fetal Medicine’s (SMFM) 2024 Pregnancy Meeting
Presentations include additional analyses of nipocalimab data from pregnancies at risk for early-onset severe HDFN; Nipocalimab is the only anti-FcRn being studied in this rare and potentially life-threatening two-person disease for which there are no approved non-surgical therapies
Contact us
Our R&D leadership team is made up of passionate individuals who are helping to transform the future of healthcare.